Bass strikes again, targets anaesthetic drug in IPR
Hedge fund manager Kyle Bass has filed another inter partes review (IPR), teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
25 November 2015 Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board review the validity of a patent owned by Alpex Pharma.
25 November 2015 Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board review the validity of a patent owned by Alpex Pharma.
25 November 2015 Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board review the validity of a patent owned by Alpex Pharma.